0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Antibody > CD19 > FABm004-02

APC-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63)

Order Now

  • Source
    Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
  • Application
    Flow Cytometry (Evaluation of the expression of CD19 on Human cells).
  • Clone
    FMC63
  • Species
    Mouse
  • Isotype
    Mouse IgG2a | Mouse kappa
  • Specificity
    This product is a specific antibody specifically reacts with CD19 protein.
  • Reactivity

    Human

  • Immunogen

    Human prolymphocytic leukaemia cell line JVM3.

  • Conjugate

    APC

    Excitation Wavelength: 640 nm

    Emission Wavelength: 661 nm

  • Isotype Control

    The Isotype control is sold separately and you can search for Cat. No. DNP-AFM487 for product information.

  • Recommended Dilution
    1:20
  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, 0.2% BSA, 0.03% Proclin 300, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. Store at 2-8 °C for 12 months.
Bioactivity-FACS
 CD19 FACS

Flow cytometric analysis of Human peripheral blood lymphocytes respectively staining with APC-Labeled Monoclonal Anti-Human CD19 Antibody Mouse IgG2a (Cat. No. FABm004-02) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with isotype control antibody. APC signal was used to evaluate the binding activity (QC tested).

  • Background
    B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
  • Clinical and Translational Updates

Comments (0)


ETA des produits en stock: 2 jours ouvrables

Price(EUR) : €410.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:11 Details
  • Number of Drugs in Clinical Trials:291 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Laisser un message